Literature DB >> 3278818

Relationship between urine beta-2-microglobulin and platinum levels during cisplatin treatment.

A A Nanji1, D J Stewart, N Z Mikhael.   

Abstract

We evaluated whether urine beta 2-microglobulin (beta 2M) excretion as a function of nephrotoxicity correlated with plasma and urine platinum levels in patients receiving cisplatin. Thirty-one patients had urine platinum measurements in urine samples collected at 0 to 6 and 6 to 24 h after cisplatin administration, 25 of these patients had serial plasma platinum measurements. Sixteen of the 31 patients had an increase in urine beta 2M. A significant correlation was obtained between urine platinum and beta 2M in the 6- to 24-h samples (r = 0.61, p less than 0.02). The mean plasma platinum levels were higher (12.6 +/- 6.1 mumol/L) in the patients with an increase in urine beta 2M compared to those patients with no change in beta 2M (6.8 +/- 4.1 mumol/L) (p less than 0.02). Our study indicates that tubular damage occurs within 24 h after cisplatin administration and that the damage correlates with urine platinum levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278818     DOI: 10.1016/s0009-9120(88)80115-2

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.

Authors:  J D Holding; W E Lindup; C van Laer; G C Vreeburg; V Schilling; J A Wilson; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

2.  Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.

Authors:  J D Holding; W E Lindup; D A Bowdler; M Z Siodlak; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  Association of Urine Platinum With Acute Kidney Injury in Children Treated With Cisplatin for Cancer.

Authors:  Asaf Lebel; Hayton Chui; Kelly R McMahon; Yong Jin Lim; Joseph Macri; Stella Wang; Prasad Devarajan; Tom D Blydt-Hansen; Michael Zappitelli; Bradley L Urquhart
Journal:  J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.